Breast cancer patients, particularly those on HER2 inhibitors, are recommended to receive cardiac monitoring at baseline, subsequently at 3 month intervals, and post therapy [19, 20], yet adherence is highly variable [10]. Here, ERBB2 is linked to breast carcinoma.